PsorX – a breakthrough for inflammatory skin diseases
“All member states of the WHO recognized the burden of psoriasis and […] that too many people in the world suffer needlessly from psoriasis due to incorrect or delayed diagnosis.” World Health Assembly 67.9, May 2014
Psoriasis and atopic dermatitis or other forms of dermatitis are amongst the most common inflammatory diseases. However, up to 50 % of patients with psoriasis and eczema are misdiagnosed due to substantial overlap between both entities. Therefore, modern biologicals and small-molecule inhibitors tailored for either psoriasis or eczema fall short of their therapeutic potential.
Over a decade of research, we have succeeded in developing a test which – based on the gene expression of NOS2 and CCL27 – detects the molecular signature of psoriasis versus eczema with very high sensitivity and specificity and thus supports a reliable differential diagnosis of these diseases.
The LabDisk-Analyzer is an in vitro diagnostic analysis instrument intended for use in the laboratory for fully automated processing of disposable in vitro diagnostic test cartridges (LabDisks) containing all reagents required for the analysis. The LabDisk-Analyzer is to be used only in combination with the application-specific LabDisks from Dermagnostix. The software integrated in the LabDisk-Analyzer calculates the test results from the measurement data generated during processing of the LabDisks in the LabDisk-Analyzer, which are then shown on the display of the LabDisk-Analyzer. The test results support the respective application-specific decisions.
As a team of leading researchers and clinicians in dermatology we are driven by moving diagnostic frontiers to achieve a breakthrough for patients with skin diseases. From our multi-omics data, we identify the most valuable biomarker combinations and translate them into easy-to-use high-tech diagnostic tools, addressing unmet clinical needs.
From our biomarker pipeline, novel tests will address clinically relevant questions for comprehensive diagnostics in dermatology.
“The diagnosis of early MF (patch stage) is particularly challenging […] This diagnosis might be elusive because MF in its early stage shares clinical and histopathological features with inflammatory benign dermatoses…and immunohistochemistry and molecular analysis have limited utility as isolated criteria“ (Torres_Cabala, 2020)
Mycosis fungoides (MF) is a malignant tumor of the skin. Using conventional methods, MF can rarely be differentiated from inflammatory diseases such as eczema in the initial stage. Adjunct techniques such as T-cell clonality analysis are of limited advantage. However, correct and early diagnosis is mandatory to enable the affected patients a normal life expectancy. We develop a gene expression based molecular test to allow early diagnosis of MF and thus a significantly better prognosis.
“Several promising biomarkers [in melanoma] show prognostic value [...], however, the scarcity of reliable data precludes the use of these biomarkers in current clinical applications” (Ding et al., 2022)
Malignant melanoma is the most prevalent cause of death among dermatological diseases. In the last decade, targeted therapies have been developed that require companion diagnostics, namely identification of driver mutations. We develop a mutation and gene expression-based test offering unparalleled value for diagnosis and prognosis of melanoma.